Skip to main content
SpringerLink
Log in

Systemic Lupus Erythematosus

  • Chapter
Therapy of Renal Diseases and Related Disorders

  • 133 Accesses

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology (1–4). Clinical features of SLE include fatigue, fever, dermatitis, photosensitivity, alopecia, arthritis, serositis, hematologic abnormalities, mucosal ulcerations, Raynaud’s phenomenon, neurological disease, and glomerulonephritis. Serologic features include false positive VDRL, antibodies to nuclear constituents, leukocytes, and erythrocytes, circulating immune complexes, and depressed complement levels. Although genetic (5), hormonal (6), and environmental (7) factors have been implicated in the etiology and modification of disease activity, immunologic abnormalities are postulated as essential in the pathogenesis of disease (8, 9). Polyclonal B cell hyperactivity with formation of large amounts of autoantibodies is characteristic of SLE (10–12). A number of effector and regulatory T cell defects have also been described (13–15). However, the clinical manifestations of disease appear to be secondary to the inflammatory response initiated by immune complexes (16,17). DNA-anti-DNA complexes may be of especial pathogeneic importance (18–20).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Osler W: On the visceral manifestions of the erythema group of skin diseases. Am J Med Sci 127: 1, 1904.

    Google Scholar 

  2. Dubois EL (ed): Lupus erythematosus A review of the current status of discoid and systemic lupus erythematosus and their variants. University of Southern California Press, Los Angeles, 1976 (2nd rev ed).

    Google Scholar 

  3. Fries JF: The clinical aspects of systemic lupus erythematosus. Med Clin North Am 61: 229, 1977.

    PubMed  CAS  Google Scholar 

  4. Tan EM, Cohen AS, Fries JF, et al: Special article: the 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271, 1982.

    PubMed  CAS  Google Scholar 

  5. Winchester RJ, Nunez-Roldan A: Some genetic aspects of systemic lupus erythematosus. Arthritis Rheum 25: 833, 1982.

    PubMed  CAS  Google Scholar 

  6. Lahita RG, Bradlow L, Fishman J, et al: Estrogen metabolism in systemic lupus erythematosus: Patients and family members. Arthritis Rheum 25: 843, 1982.

    PubMed  CAS  Google Scholar 

  7. Pincus T: Studies regarding a possible function for viruses in the pathogenesis of systemic lupus erythematosus. Arthritis Rheum 25: 847, 1982.

    PubMed  CAS  Google Scholar 

  8. Messner RP, Lindstrom FD, Williams RC Jr: Peripheral blood lymphocyte cell surface markers during the course of systemic lupus erythematosus. J Clin Invest 52: 3046, 1973.

    PubMed  CAS  Google Scholar 

  9. Fanci AS, Steinberg AD, Haynes BF, et al: Immunoregulatory aberrations in systemic Lupus erythematosus. J Immunol 121: 1473, 1978.

    Google Scholar 

  10. Koffler D, Carr RI, Agnello V, et al: Antibodies to polynucleotides in human sera antigenic specificity and relation to disease. J Exp Med 134: 294, 1971.

    PubMed  CAS  Google Scholar 

  11. Notman DD, Kurata N, Tan EM: Profiles of antinuclear antibodies in systemic rheumatic diseases. Ann Intern Med 83: 464, 1975.

    PubMed  CAS  Google Scholar 

  12. Blaese M, Grayson J, Steinberg AD: Increased immunoglobulin-secreting cells in the blood of patients with active systemic lupus erythematosus. Am J Med 69: 345, 1980.

    PubMed  CAS  Google Scholar 

  13. Paty JR JG, Sienknecht CW, Townes AS, et al: Impaired cell-mediated immunity in systemic lupus erythematosus (SLE): A controlled study of 23 untreated patients. Am J Med 59: 769, 1975.

    PubMed  Google Scholar 

  14. Abdou NI, Sagawa A, Pascual E, et al: Suppressor T-cell abnormality in idiopathic systemic lupus erythematosus. Clin Immunol immunopathol 6: 192, 1976.

    PubMed  CAS  Google Scholar 

  15. Smolen JS, Chused TM, Leiserson WM, et al: Heterogenecity of immunoregulatory t cell subsets in systemic lupus erythematosus: correlation with clinical features. Am J Med 72: 783, 1982.

    PubMed  CAS  Google Scholar 

  16. Koffler D, Agnello V, Thobum R, et al: Systemic lupus erythematosus: prototype of immune complex nephritis in man. J Exp Med 134 (S): 169, 1971.

    PubMed  CAS  Google Scholar 

  17. Bretjens J, Ossi E, Albini B, et al: Disseminated immune deposits in lupus erythematosus. Arthritis Rheum 20: 962, 1977.

    Google Scholar 

  18. Harbeck RJ, Bardana EJ, Kohler PF, et al: DNA: anti- DNA complexes: their detection in systemic lupus erythematosus sera. J Clin Invest 52: 789, 1973.

    PubMed  CAS  Google Scholar 

  19. Sano H, Morinoto C: Isolation of DNA from DNA/Anti- DNA immune complexes in systemic lupus erythematosus. J Immunol 126: 538, 1981.

    PubMed  CAS  Google Scholar 

  20. Morinoto C, Sano H, Abe T, et al: Correlation between clinical activity of systemic lupus erythematosus and the amounts of DNA in DNA/Anti-DNA antibody immune complexes. J Immunol 139: 1960, 1982.

    Google Scholar 

  21. Rudnicki RD, Gresham GE, Rothfield NF: The efficacy of antimalarials in systemic lupus erythematosus. J Rheumatol 2: 323, 1975.

    PubMed  CAS  Google Scholar 

  22. Urman JD, Rothfield NF: Corticosteroid treatment of systemic lupus erythematosus. JAMA 238: 2272, 1977.

    PubMed  CAS  Google Scholar 

  23. Carey RA, Harvey AM, Howard JE: The effect of adrenocorticotropic hormone (ACTH) and cortisone on the course of disseminated lupus erythematosus and periarteritis nodosa. Bull Johns Hopkins Hosp 87: 425, 1950.

    PubMed  CAS  Google Scholar 

  24. Klemperer P, Pollack AD, Baehr G: Pathology of disseminated lupus erythematosus. Arch Pathol 32: 569, 1941.

    CAS  Google Scholar 

  25. Pickering G, Bywaters EGL, Danielli JF, et al: Treatment of systemic lupus erythematosus with steroids. Report to the medical research council by the collagen diseases and hypersensitivity panel. Br Med J 2: 915, 1961.

    Google Scholar 

  26. Feinglass EJ, Amett FC, Dorsch CA, et al: Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other feature of the disease. Medicine 55: 323, 1976.

    PubMed  CAS  Google Scholar 

  27. Kaplan D: Treatment of systemic lupus erythematosus. Arthritis Rheum 20 (S): 175, 1977.

    Google Scholar 

  28. Merrell M, Shulman LE: Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chron Dis 1: 12, 1955.

    PubMed  CAS  Google Scholar 

  29. Kellum RE, Haserick JR: Systemic lupus erythematosus: a statistical evaluation of mortality based on a consecutive series of 299 patients. Arch Intern Med 113: 200, 1964.

    PubMed  CAS  Google Scholar 

  30. Dubois EL, Wierzchowiecki MD, Cox MB, et al: Duration and death in systemic lupus erythematosus: an analysis of 249 cases. JAMA 227: 1399, 1974.

    PubMed  CAS  Google Scholar 

  31. Leonhardt T: Long-term prognosis of systemic lupus erythematosus. Acta Med Scand 445: 440, 1966.

    CAS  Google Scholar 

  32. Estes D, Christain CL: The natural history of systemic lupus erythematosus by prospective analysis. Medicine 50: 85, 1971.

    PubMed  CAS  Google Scholar 

  33. Cameron JS, Turner DR, Ogg CS, et al: Systemic lupus with nephritis: a long-term study. Quart J Med 48: 1, 1979.

    PubMed  CAS  Google Scholar 

  34. Wallace DJ, Podell T, Weiner J, et al: Systemic lupus erythematosus - Survival patterns: experience with 609 patients. JAMA 245: 934, 1981.

    PubMed  CAS  Google Scholar 

  35. Pollack V, Pirani CL, Schwartz F: The natural history of renal manifestations of systemic lupus erythematosus. J Lab Clin Med 53: 493, 1964.

    Google Scholar 

  36. Karsh J, Klippel JH, Balow JE, et al: Mortality in lupus nephritis. Arthritis Rheum 22: 764, 1979.

    PubMed  CAS  Google Scholar 

  37. Cohen AS, Reynolds WE, Franklin EC, et al: Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis 21: 643, 1971.

    Google Scholar 

  38. Davis P, Atkins BC, Josse RG, et al: Br Med J 3: 88, 1973.

    PubMed  CAS  Google Scholar 

  39. Sinniah R, Feng PH: Lupus nephritis: correlation between light, electron microscopic and immunofluorescent findings and renal function. Clin Nephrol 6: 340, 1976.

    PubMed  CAS  Google Scholar 

  40. Wallace DJ, Podell TE, Weiner JM: Lupus nephritis: experience with 230 patients in a private practice from 1950 to 1980. Am J Med 72: 209, 1982.

    PubMed  CAS  Google Scholar 

  41. Dubis EL, Tuffanelli DL: Clinical manifestations of systemic lupus erythematosus: complete analysis of 520 cases. JAMA 190: 104, 1964.

    Google Scholar 

  42. Rothfield NF, McClusky RT, Baldwin DS: Renal disease in systemic lupus erythematosus. N Engl J Med 269: 537, 1963.

    PubMed  CAS  Google Scholar 

  43. Meislin AG, Rothfield N: Systemic lupus erythematosus in childhood. Pediatrics 42: 37, 1968.

    PubMed  CAS  Google Scholar 

  44. Dillard MG, Tillman RL, Sampson CC: Lupus nephritis: correlation between the clinical course and presence of electron-dense deposits. Lab Invest 32: 261, 1975.

    PubMed  CAS  Google Scholar 

  45. Koffler D, Agnello V, Carr I, et al: Variable patterns of immunoglobulin and complement deposition in the kidneys of pateitns with systemic lupus erythematosus. Am J Pathol 56: 305, 1969.

    PubMed  CAS  Google Scholar 

  46. Dijome I, Pollack VE, Pirani CL, et al: The distribution and character of glomerular deposits in systemic lupus erythematosus. Kidney Int 2: 23, 1972.

    Google Scholar 

  47. Pollack VE, Pirani CL: Pathology of the kidney in systemic lupus erythematosus: serial renal biopsy studies and the effects of therapy on kidney lesions. In: Dubois EL (ed) Lupus Erythematosus. University of Southern California Press, Los Angeles, 1974 (3nd ed).

    Google Scholar 

  48. Baldwin DS, Gluck MC, Lowenstein J, et al: Lupus nephritis: clinical course as related to morphologic forms and their transitions. Am J Med 62: 12, 1977.

    PubMed  CAS  Google Scholar 

  49. Earle DP Jr, Kark RM, Lange K, et al: A handbook of kidney nomenclature and nosology. Intl Comm for nomenclature and nosology of renal disease. Little, Brown, and Co, Boston, 1975, pp 56, 75.

    Google Scholar 

  50. Siegel NJ, Hayslett JP: Renal involvement in systemic lupus erythematosus. In: Suki WN, Eknoyan G (eds) The Kidney in Systemic Diseases. John Wiley, New York, 73. 1981 (2nd ed).

    Google Scholar 

  51. Comerford FR, Cohen AS: The nephropathy of systemic lupus erythematosus. An assessment of clinical, light, and electron microscopic criteria. Medicine 46: 425, 1967.

    Google Scholar 

  52. Minisiter MF, Stoller DB, Agnello V: Reassessment of the clinical significance of native DNA antibodies in systemic lupus erythematosus. Arthritis Rheum 22: 959, 1979.

    Google Scholar 

  53. Feldman MD, Huston DP, Karsh J, et al: Correlation of serum IgG, IgM, and anti-native-DNA antibodies with renal and clinical indexes of activity in systemic lupus erythematosus. J Rhemumatol 9: 52, 1982.

    CAS  Google Scholar 

  54. Zimmerman SW, Jenkins PG, Shelp WP, et al: Progression from minimal or focal to diffuse proliferative lupus nephritis. Lab Invest 32: 665, 1975.

    PubMed  CAS  Google Scholar 

  55. Grishman E, Porush JG, Lee SL, et al: Renal biopsies in lupus nephritis. Nephron 10: 25, 1973.

    PubMed  CAS  Google Scholar 

  56. Farquhar MG, Palade GE: Functional evidence for the existence of a third cell type in the renal glomerulus. J Cell Biol 13: 55, 1962.

    PubMed  CAS  Google Scholar 

  57. Haakenstad AO, Mannick M: Saturation of the reticuloendothelial system with soluble immune complexes. J. Immunol 112: 1939, 1974.

    PubMed  CAS  Google Scholar 

  58. Gershwin ME, Steinberg AD: Qualitative characteristics of anti-DNA antibodies in lupus Nephritis. Arthritis Rheum 17: 947, 1974.

    PubMed  CAS  Google Scholar 

  59. Southeimer RD, Gilliam JN: DNA antibody class, subclass, and complement fixation in systemic lupus erythematosus with and without nephritis. Clin Immunol immunopathol 10: 459, 1978.

    Google Scholar 

  60. Winfield JB, Faiferman I, Kofiler D: Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. J Clin Invest 59: 90, 1977.

    PubMed  CAS  Google Scholar 

  61. Sano H, Morimoto C: DNA isolated from DNA/anti- DNA antibody immune complexes in systemic lupus erythematosus is rich in guanine-cytosine context. J immunol 85. 128: 1341, 1982.

    Google Scholar 

  62. Decker JL, Steinberg AD, Reinertsen JL, et al: Systemic lupus erythematosus: evolving concepts. Ann Intern Med 91: 587, 1979.

    PubMed  CAS  Google Scholar 

  63. Baldwin DG, Gallo GR: Lupus nephritis. Clin Rhem Dis 1: 639, 1975.

    Google Scholar 

  64. Mery JP, Morel-Maroger L, Boelaert J, et al: Evolution anatomoclinique des glomerulites diffuses et focales an course du lupus erythemateux dissemine. J Urol Nephrol 88. 4-5: 321, 1973.

    Google Scholar 

  65. Ginzler EM, Nicastri AD, Chun-Kuo C, et al: Progression of mesangial and focal to diffuse lupus nephritis. N Engl J Med 291: 693, 1974.

    PubMed  CAS  Google Scholar 

  66. Rothfield NF: Kidney in systemic lupus erythematosus. Contrib Nephrol 7: 128, 1977.

    PubMed  CAS  Google Scholar 

  67. Baldwin DS, Lowenstein J, Rothfield NF, et al: The clinical course of proliferative and membranous forms of lupus nephritis. Ann Intern Med 73: 929, 1970.

    PubMed  CAS  Google Scholar 

  68. Fries JF, Weyl S, Holman HR: Estimating prognosis in systemic lupus erythematosus by prospective analysis. Ann J Med 57: 561, 1974.

    CAS  Google Scholar 

  69. Balow JE: Therapeutic trials in lupus nephritis-problems related to renal histology, monitoring of therapy, and measures of outcome. Nephron 27: 171, 1981.

    PubMed  CAS  Google Scholar 

  70. Coggins CH: Overview of treatment of lupus nephropathy. Am J Kid Dis 2: 197, 1982.

    PubMed  CAS  Google Scholar 

  71. Kant KS, Pollack VE, Weiss MA, et al: Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance. Medicine 60: 71, 1981.

    PubMed  CAS  Google Scholar 

  72. Symchych PS, Perrin EV: Thrombosis of mein pulmonary artery in nephrosis, thromboembolism as a complication of nephrosis. Am J Dis Child 110: 636, 1965.

    PubMed  CAS  Google Scholar 

  73. Appel GB, Williams GS, Meitzer JI, et al: Renal vein Thrombosis, nephrotic syndrome, and systemic lupus erythematosus. Ann Intern Med 85: 310, 1976.

    PubMed  CAS  Google Scholar 

  74. Cade R, Spooner G, Juncos L, et al: Chronic renal vein thrombosis. Am J Med 63: 387, 1977.

    PubMed  CAS  Google Scholar 

  75. Wegelius O: Amyloidosis of the kidneys, adrenals, and spleen as a complication of acute disseminated lupus erythematosus treated with ACTH and cortisone. Acta Med Scand 156: 91, 1956.

    PubMed  CAS  Google Scholar 

  76. Schleissner LA, Sheehan WW, Orselli RC: Lupus erythematosus in a patient with amyloidosis, adrenal insufficiency, and subsequent immunoblastic sarcoma. Arthritis Rheum 19: 249, 1976.

    PubMed  CAS  Google Scholar 

  77. King RW, Falls WF: Renal amyloidosis development in a case of systemic lupus erythematosus. Clin Nephrol 6: 467, 1976.

    Google Scholar 

  78. Webb S, Segura F, Cervantes F, et al: Systemic lupus erythematosus and amyloidosis. Arthritis Rheum 22: 554, 1979.

    PubMed  CAS  Google Scholar 

  79. Huston DP, McAdam KPWJ, Balow JE: Amyloidosis in systemic lupus erythematosus. Am J Med 70: 320, 1981.

    PubMed  CAS  Google Scholar 

  80. Budman DR, Steinberg AD: Hypertension and renal disease in systemic lupus erythematosus. Arch Intern Med 136: 1003, 1976.

    PubMed  CAS  Google Scholar 

  81. Urowitz MB, Bookman AAM, Koehier BE, et al: The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60: 221, 1976.

    PubMed  CAS  Google Scholar 

  82. Bulkley BH, Roberts WC: The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. Am J Med 58: 243, 1975.

    PubMed  CAS  Google Scholar 

  83. El-Shaboury AH, Hayes TM: Hyperlipidemia in asthmatic patients receiving long-term steroid therapy. Br Med J 2: 85, 1973.

    PubMed  CAS  Google Scholar 

  84. Hardin NJ, Minick R, Murphy GE: Experimental induction of atherosclerosis by the synergy of allergic injury to arteries and lipid rich diet. Am J Pathol 73: 301, 1973.

    PubMed  CAS  Google Scholar 

  85. Minick CR, Stemerman MB, Insull W: Role of endothelium and hypercholesterolemia in intimai thickening and lipid accumulation. Am J Pathol 95: 131, 1979.

    PubMed  CAS  Google Scholar 

  86. Klippel JH, Karsh J, Stahl NI, Decker JL, et al: A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematous. Arthritis Rheum 22: 1321, 1979.

    PubMed  CAS  Google Scholar 

  87. Friedman EA, Rutherford JW: Pregnancy and lupus erythematosus. Obstet Gynecol 8: 601, 1956.

    PubMed  CAS  Google Scholar 

  88. Garsenstein M, Pollack VE, Kark RM: Systemic lupus erythematosus and pregnancy. N Engl J Med 267: 165, 1962.

    PubMed  CAS  Google Scholar 

  89. Houser Mt, Fish AJ, Tagatz GE, et al: Pregnancy and systemic lupus erythematosus. Am J Obstet Gynecol 138: 409, 1980.

    Google Scholar 

  90. Tozman ECS, Urowitz MB, Gladman DD: Systemic lupus erythematosus and pregnancy. J Rheumatol 7: 624, 1980.

    PubMed  CAS  Google Scholar 

  91. Zulman JI, Talal N, Hoffman GS, Epstein WV: Problems associated with the management of pregnancies in patients with systemic lupus erythematosus. J Rheumatol 7: 37, 1980.

    PubMed  CAS  Google Scholar 

  92. Hayslett JP, Lynn RI: Effect of pregnancy in patients with lupus nephropathy. Kidney Int 18: 207, 1980.

    PubMed  CAS  Google Scholar 

  93. Chameides L, Truex RC, Vetter V, Rashkind WJ, et al: Association of maternal systemic lupus erythematosus with congenital complete heart block. N Engl J Med 294: 687, 1977.

    Google Scholar 

  94. McCue CM, Mantakas ME, Tingelstad JB, Ruddy S: Congenital Heart block in newborns of mothers with connective tissue disease. Circulation 56: 82, 1977.

    PubMed  CAS  Google Scholar 

  95. Helyer BJ, Howie JB: Renal disease associated with positive lupus erythematosus tests in cross-bred strains of mice. Nature 197: 197, 1963.

    PubMed  CAS  Google Scholar 

  96. Burnet FM, Holmes MC: The natural history of the NZB/NZW Fl hybrid mouse: a laboratory model of systemic lupus. Aust Ann Med 14: 185, 1965.

    PubMed  CAS  Google Scholar 

  97. Lambert Ph, Dixon FJ: Pathogenesis of the glomerulonephritis of NZB/W mice. J Exp Med 127: 507, 1968.

    PubMed  CAS  Google Scholar 

  98. Huston DP, Steinberg AD: Animal models of human systemic lupus erythematosus. Yale J Biol Med 52: 289, 1979.

    PubMed  CAS  Google Scholar 

  99. Klassen LW, Budman DR, Williams GW, et al: Ribavirin: Efficacy in the treatment of murine autoimmune disease. Science 195: 787, 1977.

    PubMed  CAS  Google Scholar 

  100. Roubinian JR, Papolan R, Talal N: Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. J Clin Invest 59: 1066, 1977.

    PubMed  CAS  Google Scholar 

  101. Duvic M, Steinberg AD, Klassen LW: Effect of anti-estrogen, Nafoxidine, on NZB/W autoimmune disease. Arthritis Rheum 21: 414, 1978.

    PubMed  CAS  Google Scholar 

  102. Melez KA, Reeves JP, Steinberg Ad: Regulation of the expression of autoimmunity in NZB × NZW F1 mice by sex hormones. J Immunopharm 1: 27, 1978.

    Google Scholar 

  103. Fretwell MD, Altman LC: Exacerbation of a lupus-erythematosus-like syndrome during treatment of non-Cl-esterase-inhibitor-dependent angioedema with danazol. J Alergy Clin Immunol 69: 306, 1982.

    CAS  Google Scholar 

  104. Krakauer RS, Strober W, Rippeon DL, et al: Prevention of autoimmune disease in experimental systemic lupus erythematosus by the administration of soluble immune response suppressor. Science 196: 56, 1977.

    PubMed  CAS  Google Scholar 

  105. Reinertsen JL, Steinberg AD: In vivo immune response suppression by the supernatant from concanavalin A-activated spleen cells. J Immunol 19: 217, 1977.

    Google Scholar 

  106. Zurier RB, Sayadoff DM, Torrey SB, et al: Prostaglandin El treatment of NZB/W mice. II Prevention of glomerulonephritis. Arthritis Rheum 20: 1449, 1977.

    PubMed  CAS  Google Scholar 

  107. Zurier RB: Prostaglandins, Immune responses, and murine lupus. Arthritis Rheum 25: 804, 1982.

    PubMed  CAS  Google Scholar 

  108. Denman AM, Denman EJ, Holborow EJ: Effects of antilymphocyte globulin on kidney disease in (NZB × NZW)Fl mice. Lancet 2: 841, 1966.

    PubMed  CAS  Google Scholar 

  109. Denman AM, Russell AS, Loewi G, et al: Immunopathology of New Zealand Black mice treated with antilymphocyte globulin. Immunology 20: 973, 1971.

    PubMed  CAS  Google Scholar 

  110. Kotzin BL, Strober S: Reversal of NZB/NZW disease with total lymphoid irradiation. J Exp Med 150: 371, 1979.

    PubMed  CAS  Google Scholar 

  111. Steinberg AD, Talal N: Suppression of antibodies to nucleic acids with polyinosinic polycytidylic and cyclophosphamide in murine lupus. Clin Exp Immunol 7: 687, 1971.

    Google Scholar 

  112. Hurd ER, Johnston JM, Okita JR, et al: Prevention of glomerulonephritis and prolonged survival in New Zealand Black/New Zealand White Fi hybrid mice fed an essential fatty acid deficient diet. J Clin Invest 67: 476, 1981.

    PubMed  CAS  Google Scholar 

  113. Prickett JD, Robinson DR, Steinberg AD: Dietary enrichment with the polyunsaturated Fatty acid eicosapentaenoic acid prevents proteinuria and prolongs survival in NZB/NZW F1 Mice. J Clin Invest 68: 556, 1981.

    PubMed  CAS  Google Scholar 

  114. Andrzejenski C Jr, Stollar BD, Lalor TM, et al: Hybridoma autoantibodies to DNA. J Immunol 124: 1499, 1980.

    Google Scholar 

  115. Hahn BH, Ebling F, Freeman S, et al: Production of monoclonal murine antibodies to DNA by somatic cell hybrids. Arthritis Rheum 23: 942, 1980.

    PubMed  CAS  Google Scholar 

  116. Rauch J, Lafer E, Andrzejewski C, et al: Monoclonal lupus autoantibodies. Arthritis Rheum 25: 744, 1982.

    PubMed  CAS  Google Scholar 

  117. Hahn B: Characteristics of pathogenic subpopulations of antibodies to DNA. Arthritis Rheum 25: 747, 1982.

    PubMed  CAS  Google Scholar 

  118. Casey TP: Systemic lupus erythematosus in NZB × NZW hybrid mice treated with the corticosteroid drug betamethasone. J Lab Clin Med 71: 390, 1968.

    PubMed  CAS  Google Scholar 

  119. Gelfand MC, Steinberg AD: Therapeutic studies in NZB/W mice. II. Relative efficacy of azathioprine, cyclophosphamide, and methylprednisone. Arthritis Rheum 15: 247, 1972.

    PubMed  CAS  Google Scholar 

  120. Hahn BH, Bagby Mk, Hamilton TR, et al: Comparison of therapeutic md immunosuppressive effects of azathioprine, prednisolone and combined therapy in NZB/NZW mice. Arthritis Rheum 16: 163, 1973.

    PubMed  CAS  Google Scholar 

  121. Steinberjg AD, Gelfand MC, Hardin JA, et al: Therapeutic studies in NZB/W mice. II. Relationship between renal status and efficacy of immunosuppressive drug therapy. Arthritis Rheum 18: 9, 1975.

    Google Scholar 

  122. Casey TP: Immunosuppression by cyclophosphamide in NZB × NZW mice with lupus nephritis. Blood 32: 436, 1968.

    PubMed  CAS  Google Scholar 

  123. Horowitz RE, Dubois EL, Weiner J, et al: Cyclophosphamide treatment of mouse systemic lupus erythematosus. Lab Invest 21: 199, 1969.

    PubMed  CAS  Google Scholar 

  124. Russell PJ, Hicks JD, Burnet FM: Cyclophosphamide treatment of kidney disease in (NZB × NZW)Fi mice. Lancet 1: 1279, 1966.

    Google Scholar 

  125. Russell PJ, Hicks JD: Cyclophosphamide treatment of renal disease in (NZB × NZW) F1 hybrid mice. Lancet 1: 440, 1968.

    PubMed  CAS  Google Scholar 

  126. Albert DA, Hadler NM, Ropes MW: Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus. Arthritis Rheum 22: 945, 1979.

    PubMed  CAS  Google Scholar 

  127. Pollack VE, Pirani CL, Kark RM: Effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulonephritis. J Lab Clin Med 57: 495, 1961.

    Google Scholar 

  128. Bell PRF, Caiman KC, Wood RFM, et al: Reversal of acute clinical and experimental organ rejection using large doses of intravenous methylprednisolone. Lancet 1: 876, 1971.

    PubMed  CAS  Google Scholar 

  129. Mussche MM, Ringoir SMG, Lameire NN: High intravenous doses of methylprednisolone for acute cadaveric renal allograft rejection. Nephron 16: 287, 1976.

    PubMed  CAS  Google Scholar 

  130. Cathcart ES, Scheinberg MA, Idelson BA, et al: Beneficial effects of methylprednisolone ‘Pulse’ therapy in diffuse proliferative lupus nephritis. Lancet 1: 163, 1976.

    PubMed  CAS  Google Scholar 

  131. Nebout T, Sobel A, Lagrue G: Intravenous methylprednisolone pulses in diffuse proliferative lupus nephritis fletter). Lancet 1: 909, 1977.

    PubMed  CAS  Google Scholar 

  132. Ponticelli C, Tarantino A, Pioltelli P, et al: High-dose methylprednisolone pulses in active lupus nephritis (letter). Lancet 1: 1063, 1977.

    PubMed  CAS  Google Scholar 

  133. Dosa S, Mallick NP, Lwler W, et al: The treatment of lupus nephritis by methylprednisolone pulse therapy. Postgrad Med J 54: 628, 1978.

    PubMed  CAS  Google Scholar 

  134. Kunberly RP, Lockshin MD, Sherman RL, et al: Highdose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus. Am J Med 70: 817, 1981.

    Google Scholar 

  135. Sztejnbok M, Stewart A, Diamond H, et al: Azathioprine in the treatment of systemic lupus erythematosus: a controlled study. Arthritis Rheum 14: 639, 1971.

    PubMed  CAS  Google Scholar 

  136. Donadio JV Jr, Holley KE, Wagoner RD, et al: Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Ann Intern Med 77: 829, 1972.

    PubMed  Google Scholar 

  137. Cade R, Spooner G, Schlein E, et al: Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis. Nephron 10: 37, 1973.

    PubMed  CAS  Google Scholar 

  138. Donadio JV Jr, Holley KE, Wagoner RD, et al: Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Arthritis Rheum 17: 573, 1974.

    PubMed  Google Scholar 

  139. Hahn BH, Kantor OS, Osteriand CK: Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus: report of a prospective controlled trial in 24 patients. Ann Intern Med 83: 597, 1975.

    PubMed  CAS  Google Scholar 

  140. Steinberg AD, Decker JL: A double-blind controlled trial comparing cyclophosphamide, azathioprine, and placebo in the treatment of lupus glomerulonephritis. Arthritis Rheum 17: 923, 1974.

    PubMed  CAS  Google Scholar 

  141. Donadio JV Jr, Holley KE, Ferguson RH, et al: Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 299: 1151, 1978.

    PubMed  Google Scholar 

  142. Ginzler E, Diamond H, Guttadauria M, et al: Prednisone and azathioprine compared to prednisone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis, arthritis Rheum 19: 693, 1976.

    PubMed  CAS  Google Scholar 

  143. Klippel JH, Steinberg AD, Balow JE, et al: Randomized study of intravenous cyclophosphamide and cyclophosphamide plus azathioprine in lupus nephritis. Arthritis Rheum (abstract) 21: 570, 1978.

    Google Scholar 

  144. Röhn RJ, Bond WH: Some effects of nitrogen mustard and triethylene malanine in acute disseminated lupus erythematosus. Am J Med Sci 226: 179, 1953.

    PubMed  Google Scholar 

  145. Dubois EL: Nitrogen mustard in the treatment of lupus erythematosus. Arch Intern Med 93: 667, 1954.

    CAS  Google Scholar 

  146. Dillard MJ, Dijome I, Pollack VE, et al: The effect of treatment with prednisone and nitrogen mustard on the renal lesions and life span of patients with lupus glomerulonephritis. Nephron 10: 273, 1973.

    PubMed  CAS  Google Scholar 

  147. Schein PS, Winokur SH: Immunosuppressive and cytotoxic chemotherapy: longterm complications. Ann Intern Med 82: 84, 1975.

    PubMed  CAS  Google Scholar 

  148. Gerber NL, Steinberg AD: Clinical use of immunosuppressive drugs: Parts 1 and 2. Drugs 11: 14, 1976.

    PubMed  CAS  Google Scholar 

  149. Plötz FH, Klippel JH, Decker JL, et al: Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med 91: 221, 1979.

    PubMed  Google Scholar 

  150. Bacon Am, Rosenberg SA: Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus. Ann Intern Med 97: 62, 1982.

    PubMed  CAS  Google Scholar 

  151. Decker JL: Cytotoxic drug benefit/risk ratio: Often too close to encourage use. Workshops in Rheumatology 3 (8): 1, 1982.

    Google Scholar 

  152. Jones JV, Cumming RH, Bucknall RC, Asplin CM: Plasmapheresis in the management of acute systemic lupus erythematosus? Lancet 1: 709, 1976.

    PubMed  CAS  Google Scholar 

  153. Jones JV, Cumming RH, Bacon PA, Evers J, Eraser ID, et al: Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus. Quart J Med 48: 555, 1979.

    PubMed  CAS  Google Scholar 

  154. Moran CJ, Parry HF: Plasmapheresis in systemic lupus erythematosus. Br Med J 1: 1573, 1977.

    PubMed  CAS  Google Scholar 

  155. Schlansky R, DeHoratius RJ, Pincus T, Tung KSK: Plasmapheresis in systemic lupus erythematosus. Arthritis Rheum 24: 49, 1981.

    PubMed  CAS  Google Scholar 

  156. Lockwood CM, Pussel B, Wilson CB, Peters DK: Plasma exchange in nephritis. Adv Nephrol 8: 383, 1979.

    CAS  Google Scholar 

  157. Lockwood CM, Peters DK: Plasma exchange in glomerulonephritis and related vasculitides. Ann Rev Med 31: 167, 1980.

    PubMed  CAS  Google Scholar 

  158. Schildermans D, Dequeker J, DePutte IV: Plasmapheresis combined with corticosteroids and cyclophosphamide in uncontrolled active systemic lupus erythematosus. J Rheumatol 6: 687, 1979.

    PubMed  CAS  Google Scholar 

  159. Lockwood CM, Rees AJ, Pussell B, et al: Experience of the use of plasma exchange in the management of potentially fulminating glomerulonephritis and SLE. Exp Hematol 5: 117s, 1977.

    Google Scholar 

  160. Hubbard HC, Portnoy B: Systemic lupus erythematosus in pregnancy treated with plasmapheresis. Br J Dermatol 101: 87, 1979.

    PubMed  CAS  Google Scholar 

  161. Isbister JP, Ralston M, Wright: Fulminant lupus pneumonitis with acute renal failure and RBC aplasia. Arch Intern Med 141: 1081, 1981.

    PubMed  CAS  Google Scholar 

  162. Fitchen JJ, Cline MJ, Saxon A, et al: Serum inhibitors of hemopoiesis in a patient with aplastic anemia and systemic lupus erythematosus: Recovery after plasma exchange. Am J Med 66: 537, 1979.

    PubMed  CAS  Google Scholar 

  163. McKenzie PE, Taylor AE, Woodroffe AJ, et al: Plasmapheresis in glomerulonephritis. Clin Nephrol 12: 97, 1979.

    PubMed  CAS  Google Scholar 

  164. Rossen RD, Hersh EM, Sharp JT, et al: Effect of plasma exchange on circulating immune complexes and antibody formation in patients with cyclophosphamide and prednisone. Am J Med 63: 674, 1977.

    PubMed  CAS  Google Scholar 

  165. Young DW, Thompson RA, McKenzie PH: Plasmapheresis in hereditary angioneurotic edema and systemic lupus erythematosus. Arch Intern Med 140: 127, 1980.

    PubMed  CAS  Google Scholar 

  166. Blacklock HA, Hill RS, Bridle M, et al: Therapeutic plasmapheresis by continuous flow centrifugation. N Z Med J 92: 145, 1980.

    PubMed  CAS  Google Scholar 

  167. Parry HF, Moran CJ, Smith ML, et al: Plasma exchange in systemic lupus erythematosus. Ann Rheum Dis 40: 224, 1981.

    PubMed  CAS  Google Scholar 

  168. Jones JV, Robinson MF, Parciany RK, et al: Therapeutic plasmapheresis in systemic lupus erythematosus: Effect on immune complexes and antibodies to DNA. Arthritis Rheum 24: 1113, 1981.

    PubMed  CAS  Google Scholar 

  169. Abdou NI, Lindsley HB, Pollock A, et al: Plasmapheresis in active SLE: Effects on clinical serum, and cellular abnormalities. Case report. Clin Immunol Immunopathol 19: 44, 1981.

    PubMed  CAS  Google Scholar 

  170. Lockwood CM, Woriledge S, Nichols A, et al: Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. N Engl J Med 300: 524, 1979.

    PubMed  CAS  Google Scholar 

  171. Clark WF, Lindsay RM, Cattran DC, et al: Monthly plasmapheresis for systemic lupus erythematosus with diffuse proliferative glomerulonephritis: A pilot study. Can Med Assoc J 125: 171, 1981.

    PubMed  CAS  Google Scholar 

  172. Terman DS, Buffaloe G, Mattioli C, Cook G, Tillquist R, Sullivan M, Ayus JC: Extracorporal immunoadsorption: initial experience in human systemic lupus erythematosus. Lancet 2: 824, 1979.

    PubMed  CAS  Google Scholar 

  173. Wei N, Klippel JH, Huston DP, et al: Randomized trial of plasma exchange in mild systemic lupus erythematosus. Lancet 1: 17, 1983.

    PubMed  CAS  Google Scholar 

  174. Huston DP, Wei N, Klima E, Hall RP, et al: Immunochemical effects of plasmapheresis in systemic lupus erythematosus (SLE). Arthritis Rheum 24: 92 (S), 1981.

    Google Scholar 

  175. Huston DP, White MJ, Mattioli C, et al: A controlled trial of plasmapheresis and cyclophosphamide therapy of lupus nephritis. Arthritis Rheum 26 (5): 33, 1983.

    Google Scholar 

  176. Eiser AR, Katz SM, Swartz C: Clinically occult diffuse proliferative lupus nephritis. Arch Intern Med 139: 1022, 1979.

    PubMed  CAS  Google Scholar 

  177. Ginzler EM, Diamond HS, Weiner M, et al: A multicenter study of outcome in systemic lupus erythematosus. I. Entry variable as predictors of prognosis. Arthritis Rheum 25: 601, 1982.

    PubMed  CAS  Google Scholar 

  178. Reidenberg MM: The chemical induction of systemic lupus erythematosus and lupus-like illnesses. Arthritis Rheum 24: 1004, 1981.

    PubMed  CAS  Google Scholar 

  179. Simon LS, Mills JA: Nonsteroidal anti-inflammatory drugs. N Engl J Med 302: 1179, 1980.

    PubMed  CAS  Google Scholar 

  180. Jüngers P, Dougados M, Pellissier C, et al: Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 25: 618, 1982.

    PubMed  Google Scholar 

  181. Mahajan SK, Ordoney NG, Spargo BH, et al: Changing histopathology patterns in lupus nephropathy. Clin Nephrol 10: 1, 1978.

    PubMed  CAS  Google Scholar 

  182. Pirani CL, Pollack VE, Schwartz FD: The reproducibility of semiquantitative analyses of renal histology. Nephron 1: 230, 1964.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. David P. Huston
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Bernard J. Hanley, Los Angeles, CA, 90033, USA

    Wadi N. Suki M.D. (Professor of Medicine Professor of Physiology and Biophysics Chief) (Professor of Medicine Professor of Physiology and Biophysics Chief)

  2. Division of Nephrology, University of Southern California School of Medicine, Los Angeles, CA, 90033, USA

    Wadi N. Suki M.D. (Professor of Medicine Professor of Physiology and Biophysics Chief) (Professor of Medicine Professor of Physiology and Biophysics Chief)

  3. Renal Section Baylor College of Medicine, The Methodist Hospital, Houston, TX, 77030, USA

    Shaul G. Massry M.D. (Professor of Medicine and Physiology Chief) (Professor of Medicine and Physiology Chief)

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Martinus Nijhoff Publishers, Boston / The Hague / Dordrecht / Lancaster

About this chapter

Cite this chapter

Huston, D.P. (1984). Systemic Lupus Erythematosus. In: Suki, W.N., Massry, S.G. (eds) Therapy of Renal Diseases and Related Disorders. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3807-9_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-3807-9_19

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-3809-3

  • Online ISBN: 978-1-4613-3807-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation